Company Overview of Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc., a drug discovery and development company, develops catalytic biopharmaceutical products based on engineered human proteases. It offers proteases for the treatment of a range of diseases with a focus on hemostasis and inflammation. The company provides recombinant human factor VIIa, IX, and Xa to treat hemophilia; and inflammation program that focuses on complement cascade, an activation component of inflammation. The company also provides FVIIa variants, including FVIIa proteases that allow use in a prophylactic setting for hemophilia patients and for the control of bleeding in normal patients in a surgical or trauma setting; and Alterase therapeutics for inflamma...
260 Littlefield Avenue
South San Francisco, CA 94080-7019
Founded in 2002
Key Executives for Catalyst Biosciences, Inc.
Chief Executive Officer and Director
Co-Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
Catalyst Biosciences, Inc. Key Developments
Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM
May 31 14
Catalyst Biosciences, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-04-2014 10:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Nassim Usman, Chief Executive Officer and Director.
Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration
Oct 9 13
Catalyst Biosciences, Inc. and Isu Abxis announced the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. Under the terms of the collaboration, Isu Abxis will use its biologics manufacturing and development expertise to advance FIX-NG through preclinical and Phase 1 studies and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an upfront licensing fee and milestone payments through the end of the Phase 1 clinical trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.
Catalyst Biosciences, Inc. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Catalyst Biosciences, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 9, 2014
November 22, 2013